Pharmacyclics and Janssen's PCI-32765 set to be gold standard for its blood cancer indication

19 February 2012

Based on clinical data and the opinions of interviewed thought leaders, Pharmacyclics (Nasdaq: PCYC) and Janssen Biotech’s (a Johnson & Johnson [NYSE: JNJ] company) PCI-32765 has earned advisory firm Decision Resources’ proprietary clinical gold standard status for the treatment of relapsed/refractory diffuse large B-cell lymphoma.

Janssen Biotech acquired rights to PCI-32765 drug candidate last year, in a deal that could earn Pharmacyclics nearly $1 billion for oncology and other indications, excluding inflammation and immune mediated conditions. (The Pharma Letter December 9, 2011).

Owing to its competitive advantages in efficacy, safety and tolerability and delivery, the Bruton’s tyrosine kinase inhibitor PCI-32765 (which is expected to launch for the indication in 2017 in the USA and Europe) will displace Decision Resources’ current proprietary clinical gold standard for relapsed/refractory diffuse large B-cell lymphoma, R-EPOCH*.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK